Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells

• Päätekijät: Mitsuki Tabata (Tekijä), Masanobu Tsubaki (Tekijä), Tomoya Takeda (Tekijä), Keisuke Tateishi (Tekijä), Katsumasa Tsurushima (Tekijä), Motohiro Imano (Tekijä), Takao Satou (Tekijä), Toshihiko Ishizaka (Tekijä), Shozo Nishida (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: BMC, 2020-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Background Current chemotherapies for Burkitt lymphoma (BL) have dramatically improved its clinical outcome. However, chemoresistance can lead to chemotherapy failure and very poor prognosis; thus, novel strategies are urgently required for patients with drug-resistant BL. To investigate th...